Cord Blood

ApprovedBiologic

JJoanne Kurtzberg, MD

Cord Blood is one of 155 biologic programs targeting Cerebral Palsy. It is currently in Approved.

Indications

Total Trials

Active Trials

154

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cerebral PalsyActive, not recruiting

EncephalopathyActive, not recruiting

Autism Spectrum DisorderActive, not recruiting

Severe Aplastic AnemiaActive, not recruiting

Type 1 DiabetesActive, not recruiting

Cerebral PalsyPhase 1/Phase 2

Active, not recruiting

EncephalopathyPhase 2

Active, not recruiting

Autism Spectrum DisorderPhase 2

Active, not recruiting

Severe Aplastic AnemiaApproved

Active, not recruiting

Type 1 DiabetesPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

384 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

Cord Blood

JJoanne Kurtzberg, MD

Approved

1 2

Symlin

AstraZeneca

Preclinical

4 3

Symlin

AstraZeneca

Preclinical

3 4

Aldomet

Neurocrine Biosciences

Preclinical

2 5

Glargine

Eli Lilly

Preclinical

4 6

Cytoxan

BBaxter Healthcare Corporation

Preclinical

1 7

Pitocin

RRetrophin

Preclinical

1 8

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 9

Foradil

Viatris

Preclinical

1 10

SGLT2 Inhibitor

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Encephalopathy1 trial

Autologous Cord Blood and Human Placental Derived Stem Cells in Neonates With Severe Hypoxic-Ischemic Encephalopathy

Withdrawn·NNew York Medical College·Phase 2·NCT02434965

Brain Injuries1 trial

Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries

Available·JJoanne Kurtzberg, MD··NCT03327467

Autism Spectrum Disorder1 trial

Cord Blood Infusion for Children With Autism Spectrum Disorder

Completed·JJoanne Kurtzberg, MD·Phase 2·NCT02847182·180 enrolled

Cerebral Palsy1 trial

Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children

Withdrawn·—·Phase 1/2·NCT01072370

Type 1 Diabetes1 trial

Umbilical Cord Blood Infusion to Treat Type 1 Diabetes

Completed·UUniversity of Florida·Phase 1/2·NCT00305344·23 enrolled

2 more indications

Transplantation1 trial

Reduced Intensity Double Umbilical Cord Blood Transplantation

Completed·MMassachusetts General Hospital·Phase 2·NCT01408563·33 enrolled

Severe Aplastic Anemia1 trial

ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia

Unknown status·JJinan Military General Hospital·Phase 4·NCT02838992·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Cord Blood. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cord Blood compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cord Blood. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Joanne Kurtzberg, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: JJoanne Kurtzberg, MD

Cord Blood

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Encephalopathy1 trial

Brain Injuries1 trial

Autism Spectrum Disorder1 trial

Cerebral Palsy1 trial

Type 1 Diabetes1 trial

Transplantation1 trial

Severe Aplastic Anemia1 trial

References

Drug Info

Quick Facts

Related News